Document is current

Article History

Received: 9 September 2024

Revised: 18 November 2024

Accepted: 19 November 2024

First Online: 12 December 2024

Declarations

:

: Paulina Kliem reports no disclosures. Kai Tisljar reports no disclosures. Pascale Grzonka reports no disclosures. Sebastian Berger reports no disclosures. Simon Amacher is supported by the Mach-Gaensslen Foundation Switzerland and the Nora van Meeuwen-Haefliger Foundation of the University of Basel, Switzerland. Gian Marco De Marchis was or is supported by the Swiss National Science Foundation; Science Funds [Wissenschaftsfonds] of the University Hospital Basel and University of Basel; Bangerter-Rhyner-Stiftung; Swisslife Jubiläumsstiftung for Medical Research; Swiss Neurological Society; Fondazione Dr. Ettore Balli; De Quervain research grant; Thermo Fisher GmbH. He received travel honoraria by Bayer and speaker honoraria by Medtronic and BMS/Pfizer. Tolga Dittrich was or is supported by the Swiss Heart Foundation, the science funds of the University Hospital Basel, and the Research fund for excellent young researchers of the University of Basel. He holds shares from Johnson & Johnson, Roche, Lilly, Bristol-Myers Squibb, Merck, and Novo Nordisk. Sabina Hunziker is supported by the Swiss National Foundation (SNF) (Ref 10001C_192850/1 and 10531C_182422), the Gottfried Julia Bangerter-Rhyner Foundation (8472/HEG-DSV), and the Swiss Society of General Internal Medicine (SSGIM). Stephan Rüegg received unconditional research grants from UCB-pharma. He received honoraria from serving on the scientific advisory boards of Arvelle, Eisai, and UCB-pharma, and from serving as a consultant for Arvelle, Eisai, Pfizer, Novartis, Sandoz, and UCB-pharma. He does not hold any stocks of any pharmaceutical industries or manufacturers of medical devices. He received funding from UCB-pharma, and Swiss National Science Foundation Grants: grant number 320030_169379/1 and coapplicant for grants numbers 33CM30_125115/1 and 33CM30_140338/1; he disclosed that he is the past president of the Swiss League against Epilepsy (no payments), Editor of EPILEPTOLOGIE (Journal of the Swiss League against Epilepsy) (no payments), and Editor of the Swiss EEG Bulletin (payments from UCB). Stefano Bassetti reports no disclosures. Roland Bingisser reports no disclosures. Stephan Marsch reports no disclosures. Raoul Sutter received research grants from the Swiss National Foundation (No 320030_169379), the Research Fund of the University Basel, the Scientific Society Basel, and the Gottfried Julia Bangerter-Rhyner Foundation. He received personal grants from UCB-pharma and holds stocks from Novartis, Roche, Alcon, and Johnson & Johnson.

: The study was approved by the local ethics committee (EKNZRequ_2019-00168), who ascertained that this study complies with the general ethical principles for research involving human subjects (according to article 51(2) of the Human Research Act). Consent was received from the volunteering physicians for the anonymized analyses of the video- and audio recordings of their performances. The Reporting Guidelines for Health Care Simulation Research—and extensions to the CONSORT (CONsolidated Standards Of Reporting Trials) and STROBE (Strengthening The Reporting of OBservational studies in Epidemiology) Statements—for randomized trials were followed. The study was retrospectively registered online (last amendment 08/22/2023) at the digital SRCTN registry (ID ISRCTN12257237) [].

: Consent for publication was obtained from our author P.G. (seen in the picture) to portray a participating physician in Fig. .